Initial Public Offering

Healthcare
Initial Public Offering

Summary

Baird served as a co-manager in this offering

About

Complete Genomics, Inc. (NASDAQ:GNOM) (“Complete Genomics” or the “Company”) recently announced the pricing of its initial public offering of 6,000,000 shares of common stock at $9.00 per share, generating gross proceeds of $54.0 million for the Company. The Company intends to use the net proceeds from the offering for capital expenditures to expand the sequencing and computing capacity in its Mountain View and Santa Clara leased facilities, to finance the further development of its sequencing technology and services, for sales and marketing activities, and for working capital and other general corporate purposes. Complete Genomics offered all of the 6,000,000 shares of common stock and has granted the underwriters an option to purchase an additional 900,000 shares to cover over-allotments.

Complete Genomics is a life sciences company that has developed and commercialized an innovative DNA sequencing platform. The Complete Genomics Analysis Platform (CGA™ Platform) combines Complete Genomics’ proprietary human genome sequencing technology with its advanced informatics and data management software and its innovative, end-to-end, outsourced service model to provide customers with data that is immediately ready to be used for genome-based research.

For additional information about this transaction, please contact:

Frank Stokes (704) 553-6610
Greg Ingram (415) 627-3279
Peter Kies (414) 765-7262
Ryan Mausehund (650) 858-3817
Healthcare
Initial Public Offering
Date
November 2010
Company
Complete Genomics, Inc.
Transaction
M&A
Sectors
Healthcare
Target Location
North America

Share